Mitochondrial Aging Diseases

Mitochondrial diseases are a group of disorders caused by dysfunctional mitochondria, the organelles that generate energy for the cell. Mitochondria are found in every cell of the human body except red blood cells, and convert the energy of food molecules into the ATP that powers most cell functions.

Mitochondrial diseases are sometimes (about 15% of the time)[1] caused by mutations in the mitochondrial DNA that affect mitochondrial function. Other mitochondrial diseases are caused by mutations in genes of the nuclear DNA, whose gene products are imported into the mitochondria (mitochondrial proteins) as well as acquired mitochondrial conditions. Mitochondrial diseases take on unique characteristics both because of the way the diseases are often inherited and because mitochondria are so critical to cell function. The subclass of these diseases that have neuromuscular disease symptoms are often called a mitochondrial myopathy.

Symptoms include: poor growth, loss of muscle coordination, muscle weakness, visual problems, hearing problems, learning disabilities, heart disease, liver disease, kidney disease, gastrointestinal disorders, respiratory disorders, neurological problems, autonomic dysfunction and dementia.[2] Acquired conditions in which mitochondrial dysfunction has been involved are: diabetes, Huntington’s disease, cancer, Alzheimer’s disease, Parkinson’s disease, bipolar disorder,[3][4][5] schizophrenia, aging and senescence, anxiety disorders, cardiovascular disease, sarcopenia and chronic fatigue syndrome.[6]

The body, and each mutation, is modulated by other genome variants; the mutation that in one individual may cause liver disease might in another person cause a brain disorder. The severity of the specific defect may also be great or small. Some defects include “exercise intolerance”. Defects often affect the operation of the mitochondria and multiple tissues more severely, leading to multi-system diseases.[7]

As a rule, mitochondrial diseases are worse when the defective mitochondria are present in the muscles, cerebrum, or nerves,[8] because these cells use more energy than most other cells in the body.

Although mitochondrial diseases vary greatly in presentation from person to person, several major clinical categories of these conditions have been defined, based on the most common phenotypic features, symptoms, and signs associated with the particular mutations that tend to cause them.[citation needed]

An outstanding question and area of research is whether ATP depletion or reactive oxygen species are in fact responsible for the observed phenotypic consequences.[citation needed]

Cerebellar atrophy or hypoplasia has sometimes been reported to be associated.[9]

Mitochondrial disorders may be caused by mutations (acquired or inherited), in mitochondrial DNA (mtDNA), or in nuclear genes that code for mitochondrial components. They may also be the result of acquired mitochondrial dysfunction due to adverse effects of drugs, infections, or other environmental causes (see MeSH).

Nuclear DNA has two copies per cell (except for sperm and egg cells), one copy being inherited from the father and the other from the mother. Mitochondrial DNA, however, is strictly inherited from the mother and each mitochondrial organelle typically contains between 2 and 10 mtDNA copies. During cell division the mitochondria segregate randomly between the two new cells. Those mitochondria make more copies, normally reaching 500 mitochondria per cell. As mtDNA is copied when mitochondria proliferate, they can accumulate random mutations, a phenomenon called heteroplasmy. If only a few of the mtDNA copies inherited from the mother are defective, mitochondrial division may cause most of the defective copies to end up in just one of the new mitochondria (for more detailed inheritance patterns, see human mitochondrial genetics). Mitochondrial disease may become clinically apparent once the number of affected mitochondria reaches a certain level; this phenomenon is called “threshold expression”.

Mitochondrial DNA mutations occur frequently, due to the lack of the error checking capability that nuclear DNA has (see Mutation rate). This means that mitochondrial DNA disorders may occur spontaneously and relatively often. Defects in enzymes that control mitochondrial DNA replication (all of which are encoded for by genes in the nuclear DNA) may also cause mitochondrial DNA mutations.

Most mitochondrial function and biogenesis is controlled by nuclear DNA. Human mitochondrial DNA encodes 13 proteins of the respiratory chain, while most of the estimated 1,500 proteins and components targeted to mitochondria are nuclear-encoded. Defects in nuclear-encoded mitochondrial genes are associated with hundreds of clinical disease phenotypes including anemia, dementia, hypertension, lymphoma, retinopathy, seizures, and neurodevelopmental disorders.[10]

A study by Yale University researchers (published in the February 12, 2004 issue of the New England Journal of Medicine) explored the role of mitochondria in insulin resistance among the offspring of patients with type 2 diabetes.[11] Other studies have shown that the mechanism may involve the interruption of the mitochondrial signaling process in body cells (intramyocellular lipids). A study conducted at the Pennington Biomedical Research Center in Baton Rouge, Louisiana[12] showed that this, in turn, partially disables the genes that produce mitochondria.

Examples of mitochondrial diseases include:

  • Mitochondrial myopathy
  • Diabetes mellitus and deafness (DAD)
    • this combination at an early age can be due to mitochondrial disease
    • Diabetes mellitus and deafness can be found together for other reasons
  • Leber’s hereditary optic neuropathy (LHON)
    • visual loss beginning in young adulthood
    • eye disorder characterized by progressive loss of central vision due to degeneration of the optic nerves and retina
    • affects 1 in 50,000 people in Finland
  • Leigh syndrome, subacute sclerosing encephalopathy
    • after normal development the disease usually begins late in the first year of life, although onset may occur in adulthood
    • a rapid decline in function occurs and is marked by seizures, altered states of consciousness, dementia, ventilatory failure
  • Neuropathy, ataxia, retinitis pigmentosa, and ptosis (NARP)
    • progressive symptoms as described in the acronym
    • dementia
  • Myoneurogenic gastrointestinal encephalopathy (MNGIE)
    • gastrointestinal pseudo-obstruction
    • neuropathy
  • Myoclonic Epilepsy with Ragged Red Fibers (MERRF)
    • progressive myoclonic epilepsy
    • “Ragged Red Fibers” are clumps of diseased mitochondria that accumulate in the subsarcolemmal region of the muscle fiber and appear when muscle is stained with modified Gömöri trichrome stain
    • short stature
    • hearing loss
    • lactic acidosis
    • exercise intolerance
  • Mitochondrial myopathy, encephalomyopathy, lactic acidosis, stroke-like symptoms (MELAS)
  • mtDNA depletion
    • mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)

Conditions such as Friedreich’s ataxia can affect the mitochondria but are not associated with mitochondrial proteins.

The effective overall energy unit for the available body energy is referred to as the daily glycogen generation capacity,[13][14][15] and is used to compare the mitochondrial output of healthy individuals to that of afflicted or chronically glycogen-depleted individuals. This value is slow to change in a given individual, as it takes between 18 and 24 months to complete a full cycle.[14]

The glycogen generation capacity is entirely dependent on, and determined by, the operating levels of the mitochondria in all of the cells of the human body;[16] however, the relation between the energy generated by the mitochondria and the glycogen capacity is very loose and is mediated by many biochemical pathways.[13] The energy output of full healthy mitochondrial function can be predicted exactly by a complicated theoretical argument, but this argument is not straightforward, as most energy is consumed by the brain and is not easily measurable.

Mitochondrial diseases are usually detected by analysing muscle samples, where the presence of these organelles is higher. The most common tests for the detection of these diseases are:

  1. Southern blot to detect big deletions or duplications
  2. PCR and specific mutation analysis
  3. Sequencing

Although research is ongoing, treatment options are currently limited; vitamins are frequently prescribed, though the evidence for their effectiveness is limited.[17] Pyruvatehas been proposed in 2007 as a treatment option.[18] N-acetyl cysteine reverses many models of mitochondrial dysfunction.[19]. In the case of mood disorders, specifically bipolar disorder, it is hypothesized that N-acetyl-cysteine (NAC), acetyl-L-carnitine (ALCAR), S-adenosylmethionine (SAMe), coenzyme Q10 (CoQ10), alpha-lipoic acid (ALA), creatine monohydrate (CM), and melatonin could be potential treatment options. [20]

Spindle transfer, where the nuclear DNA is transferred to another healthy egg cell leaving the defective mitochondrial DNA behind, is a potential treatment procedure that has been successfully carried out on monkeys.[21][22] Using a similar pronuclear transfer technique, researchers at Newcastle University led by Douglass Turnbullsuccessfully transplanted healthy DNA in human eggs from women with mitochondrial disease into the eggs of women donors who were unaffected.[23][24] In such cases, ethical questions have been raised regarding biological motherhood, since the child receives genes and gene regulatory molecules from two different women. Using genetic engineering in attempts to produce babies free of mitochondrial disease is controversial in some circles and raises important ethical issues.[25][26] A male baby was born in Mexico in 2016 from a mother with Leigh syndrome using spindle transfer.[27]

In September 2012 a public consultation was launched in the UK to explore the ethical issues involved.[28] Human genetic engineering was used on a small scale to allow infertile women with genetic defects in their mitochondria to have children.[29] In June 2013, the United Kingdom government agreed to develop legislation that would legalize the ‘three-person IVF’ procedure as a treatment to fix or eliminate mitochondrial diseases that are passed on from mother to child. The procedure could be offered from 29 October 2015 once regulations had been established.[30][31][32] Embryonic mitochondrial transplant and protofection have been proposed as a possible treatment for inherited mitochondrial disease, and allotopic expression of mitochondrial proteins as a radical treatment for mtDNA mutation load.

In June 2018 Australian Senate’s Senate Community Affairs References Committee recommended a move towards legalising Mitochondrial replacement therapy (MRT). Research and clinical applications of MRT were overseen by laws made by federal and state governments. State laws were, for the most part, consistent with federal law. In all states, legislation prohibited the use of MRT techniques in the clinic, and except for Western Australia, research on a limited range of MRT was permissible up to day 14 of embryo development, subject to a license being granted. In 2010, the Hon. Mark Butler MP, then Federal Minister for Mental Health and Ageing, had appointed an independent committee to review the two relevant acts: the Prohibition of Human Cloning for Reproduction Act 2002 and the Research Involving Human Embryos Act 2002. The committee’s report, released in July 2011, recommended the existing legislation remain unchanged

Currently, human clinical trials are underway at GenSight Biologics ( # NCT02064569) and the University of Miami ( # NCT02161380) to examine the safety and efficacy of mitochondrial gene therapy in Leber’s hereditary optic neuropathy.

About 1 in 4,000 children in the United States will develop mitochondrial disease by the age of 10 years. Up to 4,000 children per year in the US are born with a type of mitochondrial disease.[33] Because mitochondrial disorders contain many variations and subsets, some particular mitochondrial disorders are very rare.

The average number of births per year among women at risk for transmitting mtDNA disease is estimated to approximately 150 in the United Kingdom and 800 in the United States.[34]

The first pathogenic mutation in mitochondrial DNA was identified in 1988; from that time to 2016, around 275 other disease-causing mutations were identified.[35]:37

Notable people who suffered from mitochondrial disease include:

  • Mattie Stepanek, a poet, peace advocate, and motivational speaker who suffered from dysautonomic mitochondrial myopathy, and who died at age 13.
  • Rocco Baldelli, a coach and former center fielder in Major League Baseball who had to retire from active play at age 29 due to mitochondrial channelopathy.
  • Charlie Gard, a British boy who suffered from mitochondrial DNA depletion syndrome; decisions about his care were taken to various law courts.
  • Greg Lemond, American champion cyclist that developed mitochondrial myopathy after being shot in a hunting accident. Aluminum leached into his bloodstream from the remaining shotgun pellets that surgeons were unable to remove.

  1. ^ DiMauro, Salvatore; Davidzon, Guido (2005). “Mitochondrial DNA and disease”. Annals of Medicine. 37 (3): 222–232. doi:10.1080/07853890510007368. PMID 16019721.
  2. ^ Nenad Blau; Marinus Duran; K Michael Gibson; Carlo Dionisi Vici (2014-07-08). Physician’s Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases. Springer. pp. 339–. ISBN 978-3-642-40337-8.
  3. ^ Stork, C; Renshaw, P F (2005). “Mitochondrial dysfunction in bipolar disorder: Evidence from magnetic resonance spectroscopy research”. Molecular Psychiatry. 10 (10): 900–19. doi:10.1038/ PMID 16027739.
  4. ^ Pieczenik, Steve R; Neustadt, John (2007). “Mitochondrial dysfunction and molecular pathways of disease”. Experimental and Molecular Pathology. 83 (1): 84–92. doi:10.1016/j.yexmp.2006.09.008. PMID 17239370.
  5. ^ Nierenberg, Andrew A; Kansky, Christine; Brennan, Brian P; Shelton, Richard C; Perlis, Roy; Iosifescu, Dan V (2012). “Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development”. Australian & New Zealand Journal of Psychiatry. 47 (1): 26–42. doi:10.1177/0004867412449303. PMID 22711881.
  6. ^ Pieczenik, Steve R; Neustadt, John (2007). “Mitochondrial dysfunction and molecular pathways of disease”. Experimental and Molecular Pathology. 83 (1): 84–92. doi:10.1016/j.yexmp.2006.09.008. PMID 17239370.
  7. ^ Nunnari J, Suomalainen A (2012). “Mitochondria: in sickness and in health”. Cell. 148 (6): 1145–59. doi:10.1016/j.cell.2012.02.035. PMC 5381524. PMID 22424226.
  8. ^ Finsterer, Josef (2007). “Hematological Manifestations of Primary Mitochondrial Disorders”. Acta Haematologica. 118 (2): 88–98. doi:10.1159/000105676. PMID 17637511.
  9. ^ Lax, Nichola Zoe; Hepplewhite, Philippa Denis; Reeve, Amy Katherine; Nesbitt, Victoria; McFarland, Robert; Jaros, Evelyn; Taylor, Robert William; Turnbull, Douglass Matthew (2012). “Cerebellar Ataxia in Patients with Mitochondrial DNA Disease”. Journal of Neuropathology & Experimental Neurology. 71 (2): 148–61. doi:10.1097/NEN.0b013e318244477d. PMC 3272439. PMID 22249460.
  10. ^ Scharfe C, Lu HH, Neuenburg JK, Allen EA, Li GC, Klopstock T, Cowan TM, Enns GM, Davis RW (2009). Rzhetsky A, ed. “Mapping gene associations in human mitochondria using clinical disease phenotypes”. PLoS Comput Biol. 5(4): e1000374. doi:10.1371/journal.pcbi.1000374. PMC 2668170. PMID 19390613.
  11. ^ Petersen, Kitt Falk; Dufour, Sylvie; Befroy, Douglas; Garcia, Rina; Shulman, Gerald I. (2004). “Impaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 Diabetes”. New England Journal of Medicine. 350 (7): 664–671. doi:10.1056/NEJMoa031314. ISSN 0028-4793. PMC 2995502.
  12. ^ Diabetes 54, 2005 1926-33
  13. ^ Jump up to: a b Mitchell, Peter. “David Keilin`s respiratory chain concept and its chemiosmotic consequences” (PDF). Nobel institute.
  14. ^ Jump up to: a b Michelakis, Evangelos (January 2007). “A Mitochondria-K+ Channel Axis Is Suppressed in Cancer and Its Normalization Promotes Apoptosis and Inhibits Cancer Growth”. University of Alberta. University of Alberta, 2007. 11: 37–51. doi:10.1016/j.ccr.2006.10.020. PMID 17222789.
  15. ^ Lorini & Ciman, M, & M. “Hypoglycaemic action of Diisopropylammonium salts in experimental diabetes”. Institute of Biochemistry, University of Padua, September 1962. Biochemical Pharmacology. 11: 823–827. doi:10.1016/0006-2952(62)90177-6.
  16. ^ Stacpoole PW, Henderson GN, Yan Z, James MO (1998). “Clinical pharmacology and toxicology of dichloroacetate”. Environ. Health Perspect. 106 Suppl 4: 989–94. doi:10.1289/ehp.98106s4989. PMC 1533324. PMID 9703483.
  17. ^ Marriage B, Clandinin MT, Glerum DM (2003). “Nutritional cofactor treatment in mitochondrial disorders”. J Am Diet Assoc. 103 (8): 1029–38. doi:10.1016/S0002-8223(03)00476-0. PMID 12891154.
  18. ^ Tanaka M, Nishigaki Y, Fuku N, Ibi T, Sahashi K, Koga Y (2007). “Therapeutic potential of pyruvate therapy for mitochondrial diseases”. Mitochondrion. 7 (6): 399–401. doi:10.1016/j.mito.2007.07.002. PMID 17881297.
  19. ^ Frantz MC, Wipf P. Mitochondria as a target in treatment. Environ Mol Mutagen. 2010 Jun;51(5):462-75. doi:10.1002/em.20554
  20. ^ Nierenberg, Andrew A, Kansky, Christine, Brennan, Brian P, Shelton, Richard C, Perlis, Roy, Iosifescu, Dan V (2012). “Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development”. Australian & New Zealand Journal of Psychiatry. 47: 26–42. doi:10.1177/0004867412449303.
  21. ^ Genetic advance raises IVF hopes By Pallab Ghosh. BBC News, science correspondent. Page last updated at 17:04 GMT, Wednesday, 26 August 2009 18:04 UK
  22. ^ Tachibana M, Sparman M, Sritanaudomchai H, Ma H, Clepper L, Woodward J, Li Y, Ramsey C, Kolotushkina O, Mitalipov S (September 2009). “Mitochondrial gene replacement in primate offspring and embryonic stem cells”. Nature. 461 (7262): 367–372. doi:10.1038/nature08368. PMC 2774772. PMID 19710649.
  23. ^ Boseley, Sarah (2010-04-14). “Scientists reveal gene-swapping technique to thwart inherited diseases”. London: Guardian.
  24. ^ Craven, Lyndsey; Tuppen, Helen A.; Greggains, Gareth D.; Harbottle, Stephen J.; Murphy, Julie L.; Cree, Lynsey M.; Murdoch, Alison P.; Chinnery, Patrick F.; Taylor, Robert W.; Lightowlers, Robert N.; Herbert, Mary; Turnbull, Douglass M. (2010). “Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease”. Nature. 465 (7294): 82–85. doi:10.1038/nature08958. PMC 2875160. PMID 20393463. open access publication – free to read
  25. ^ “UK urged to permit IVF procedure to prevent fatal genetic diseases”. London: The Guardian. 2015-04-30.
  26. ^ “Three parent baby law is ‘irresponsible’ says Church of England ahead of vote”. London: The Telegraph. 2015-04-30.
  27. ^ Hamzelou, Jessica (2016-09-27). “Exclusive: World’s first baby born with new “3 parent” technique”. New Scientist. Retrieved 2016-11-26.
  28. ^ Sample, Ian (2012-09-17). “Regulator to consult public over plans for new fertility treatments”. The Guardian. London. Retrieved 8 October 2012.
  29. ^ “Genetically altered babies born”. BBC News. 2001-05-04. Retrieved 2008-04-26.
  30. ^ The Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015 No. 572
  31. ^ “UK government backs three-person IVF”. BBC News. 27 June 2013.
  32. ^ Knapton, Sarah (1 March 2014) ‘Three-parent babies’ could be born in Britain next year The Daily Telegraph Science News, Retrieved 1 March 2014
  33. ^ The Mitochondrial and Metabolic Disease Center
  34. ^ Gorman, Gráinne S.; Grady, John P.; Ng, Yi; Schaefer, Andrew M.; McNally, Richard J.; Chinnery, Patrick F.; Yu-Wai-Man, Patrick; Herbert, Mary; Taylor, Robert W.; McFarland, Robert; Turnbull, Doug M. (2015). “Mitochondrial Donation — How Many Women Could Benefit?”. New England Journal of Medicine. 372: 150130091413004. doi:10.1056/NEJMc1500960. ISSN 0028-4793. PMC 4481295.
  35. ^ Committee on the Ethical and Social Policy Considerations of Novel Techniques for Prevention of Maternal Transmission of Mitochondrial DNA Diseases; Board on Health Sciences Policy; Institute of Medicine (2016). Claiborne, Anne; English, Rebecca; Kahn, Jeffrey, eds. Mitochondrial Replacement Techniques: Ethical, Social, and Policy Considerations. National Academies Press. ISBN 978-0-309-38870-2. Index page with links to summaries including one page summary flyer.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Recent Posts

Recent Comments


error: Content is protected !!

Have a good day